All Articles

Browse the full archive, newest first.

Briefing: ‘Weakening climate leadership’: Is the EU’s 2040 emissions target ambitious enough?

Strategic angle: Experts warn that the EU’s interim climate targets are being ‘undermined’ by a loophole that comes into effect in 2036.

Editorial Staff Mar 12

Politics

Briefing: Iran war: Oil prices spike as Iran steps up tanker attacks

Strategic angle: Iran is continuing to target energy infrastructure across the Gulf, causing significant disruptions in oil supply.

Editorial Staff Mar 12

Money

Briefing: Deutsche Bank Seeks to Expand Private Credit Offerings

Strategic angle: German lender emphasizes conservative underwriting standards amid industry concerns.

Editorial Staff Mar 12

Politics

Briefing: China passes controversial 'ethnic unity' law

Strategic angle: The new law mandates Mandarin as the official language, raising concerns over minority rights.

Editorial Staff Mar 12

Travel

Briefing: Not A Golf Yet: Volkswagen ID.3 Becomes The ID.3 Neo

Strategic angle: In mid-April 2026, the extensive facelift will be unveiled, and there will be real buttons again.

Editorial Staff Mar 12

Tech

Briefing: Big Data on the Cheapest MacBook

Strategic angle: Exploring the capabilities of budget-friendly MacBook for big data applications.

Editorial Staff Mar 12

Politics

Briefing: Ukraine's Zelensky to meet with Macron in Paris on Friday

Strategic angle: President Zelensky aims to discuss increasing sanctions on Russia during his European tour.

Editorial Staff Mar 12

Travel

Briefing: Honda Cancels 0 Sedan, 0 SUV, And Acura RSX EVs

Strategic angle: Honda announces significant losses in its electric vehicle division while reevaluating its future strategy.

Editorial Staff Mar 12

Politics

Briefing: How Paris mobility transformed under Anne Hidalgo's two terms

Strategic angle: Between 2014 and 2026, the streets of Paris underwent sweeping changes, notably with the pedestrianization of the riverbanks and the creation of numerous bike lanes.

Editorial Staff Mar 12

Life

Briefing: STAT+: Is Aldeyra Therapeutics waving red flags with consequences?

Strategic angle: How often do drugmakers complain about short sellers in SEC filings? And does it do any good?

Editorial Staff Mar 12